Nimish Shah
A5002478152- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Liver Disease Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Liver Disease and Transplantation
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Cutaneous lymphoproliferative disorders research
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Infectious Diseases and Tuberculosis
- Biosimilars and Bioanalytical Methods
- Tuberculosis Research and Epidemiology
- Kidney Stones and Urolithiasis Treatments
- Ureteral procedures and complications
- Genetic and Kidney Cyst Diseases
- Medical Imaging Techniques and Applications
- Cancer Genomics and Diagnostics
- Diagnosis and treatment of tuberculosis
- Digital and Cyber Forensics
- Digital Imaging for Blood Diseases
- Ethics in Clinical Research
- Congenital gastrointestinal and neural anomalies
SRM University, Andhra Pradesh
2024
Norfolk and Norwich University Hospitals NHS Foundation Trust
2017-2024
Derriford Hospital
2012-2023
Norfolk and Norwich University Hospital
2017-2023
University of Leeds
2023
St James's University Hospital
2023
Peterborough City Hospital
2023
University of Southampton
2023
James Paget University Hospitals NHS Foundation Trust
2023
Cancer Research UK
2023
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study characterize course COVID-19 in and identify potential predictors outcome. Of 190 confirmed diagnosed between 28/03/2020 22/05/2020, 151 (79%) presented (need oxygen and/or intensive care admission). Severe was associated advanced...
Abstract MYC translocation occurs in 8–14% of diffuse large B-cell lymphoma (DLBCL), and may concur with BCL2 and/or BCL6 translocation, known as double-hit (DH) or triple-hit (TH). DLBCL- / -DH/TH are largely germinal centre like subtype, but show variable clinical outcome, IG :: fusion significantly associated inferior survival. While -DH their cell-of-origin subtypes outcome. Intriguingly, only 40-50% DLBCL high protein expression (>70%). We studied 186 DLBCLs including 32...
Summary Venetoclax is a BCL 2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia ( CLL ). We conducted multi‐centre retrospective analysis of 105 R/R patients who received venetoclax pre‐National Health Service commissioning. The median age was 67 years and prior lines 3 (range: 1–15). 48% had TP 53 disruption. At ≥2 lines, 60% Bruton Tyrosine Kinase BTK i) no phosphoinositide 3‐kinase (Pi3Ki), 25% Pi3Ki i, 10% both. Patients discontinued B cell receptor BCR...
[4] For patients who are not eligible for SCT or CAR T-cell therapy and those with progressive disease (PD) after therapy, outcomes remain poor new approaches required. 1[7][8] In the randomized phase 2 G029365 trial, polatuzumab vedotin (an anti-CD79b monoclonal antibody conjugated to cytotoxin monomethyl auristatin E) bendamustine rituximab (Pola-BR) was compared bendamustine-rituximab treatment of relapsed/refractory (R/R) DLBCL in ineligible SCT.For Pola-BR, objective response rate (ORR)...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors immunoarchitectural patterns (IAPs) for all stages pediatric adult patients with NLPHL.
Abstract High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there limited evidence to guide whether intercalate HD-MTX (i-HD-MTX) between R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone given 21-day intervals) or give it the end treatment (EOT) R-CHOP-21. We conducted a retrospective, multicenter analysis 334 DLBCL who...
DIRECT was a prospective, multisite study assessing the feasibility and utility of circulating tumor DNA (ctDNA) in 188 patients with aggressive B-cell non-Hodgkin lymphoma using lymphoma-customized assay open-source pipeline. CtDNA fraction assessed by copy number alterations pre-treatment plasma identified high-risk more effectively than existing clinical risk scores. In 74.5% cases ctDNA equivalent or superior to biopsy for genetic profiling. Patients not suitable genotyping had low...
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. also features annotations, reviews, short reports, images haematology Letters to the Editor.
Summary Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front‐line ‘attenuated’ or low‐intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report of attenuated 95 with MCL across 19 centres the UK and Ireland considered for full‐dose rituximab‐bendamustine rituximab‐cyclophosphamide, doxorubicin, vincristine, prednisolone (R‐CHOP). Regimens examined were (R‐CVP) ( n = 19), dose‐attenuated R‐CHOP...
Abstract Treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or escalated(e)-BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) remains the international standard of care for advanced-stage classical Hodgkin lymphoma (HL). We performed a retrospective, multicentre analysis 221 non-trial (“real-world”) patients, aged 16–59 years, diagnosed HL in Anglia Cancer Network between 2004 2014, treated eBEACOPP, compared...
Summary Serum free light C hain (s FLC ) ratios have been correlated with survival outcomes in H odgkin and non‐ lymphoma subtypes. This study was undertaken to investigate the prognostic impact of abnormal s mantle cell ( MCL ). two patient cohorts were analysed for parameters: a preliminary retrospective cohort uniformly treated 20 relapsed/refractory patients, enrolled phase II clinical trial single agent lenalidomide treatment. 52% patients had an abnormality one or more parameter (71%...
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma. It can follow heterogeneous clinical course but generally patients relapse early after standard immunochemotherapy regimens develop resistance to subsequent therapies. For younger patients, intensive approaches followed by autologous stem transplantation offer excellent long-term disease control with the possible exception an allogenic transplant, MCL incurable condition. As principally affects older...